Bayer Leverages AI, Precision Medicine, and Pipeline Growth to Drive 2030 Strategy

Bayer has outlined its growth strategy toward 2030, driven by an AI-enabled operating model, a strengthened pharmaceutical pipeline, and a focus on precision medicine across oncology, cardiovascular disease, and women's health. The company is on track to return to mid-single-digit growth from 2027 while expanding margins toward 30 percent by 2030.

Speaking at its Pharma Media Day 2026, a member of the Board of Management and president of the Pharmaceuticals Division stated that the company was beginning to see tangible outcomes from its transformation strategy, backed by its strongest-ever pharma portfolio and a differentiated multimodal pipeline.

Bayer has entered into a partnership with Iambic Therapeutics to use AI-powered technology in small molecule discovery and drug development. The collaboration will focus on drug targets that have been difficult to reach through traditional methods. Bayer will access Iambic's Enchant and NeuralPLexer AI platforms, which could help identify new drug pathways and reduce optimization timelines. The partnership provides Bayer with access to external AI capabilities rather than developing comparable systems internally.

AI is emerging as a central enabler of Bayer's long-term strategy. The company aims to increase R&D productivity by 40 percent by 2030 through the integration of AI platforms with anonymized patient-centric data. Strategic collaborations with Vanderbilt University Medical Centre, FinnGen, and PRECISE are helping Bayer leverage large-scale datasets and advanced analytics to accelerate drug discovery. A partnership with tech firm Cradle is expected to shorten development timelines and improve molecule design precision.

Bayer's research division works in specialty areas including Oncology, Cardiology, Neurology, Women's Health, and Cell and Gene Therapies, managing 40 active programs. The company's innovation portfolio comprises 45 percent biologics and advanced therapies alongside 55 percent small molecules.

In cardiovascular care, Bayer is advancing next-generation therapies for secondary stroke prevention by targeting factor XIa in the coagulation pathway, aiming to decouple thrombosis from hemostasis. The company is also making progress in treating transthyretin amyloidosis with cardiomyopathy, introducing a therapy in Europe that stabilizes the transthyretin protein. Its investigational therapy targeting mineralocorticoid receptor over-activation has been evaluated across five clinical trials.

Oncology remains a core growth pillar. Bayer is advancing second-generation androgen receptor inhibitors targeting metastatic hormone-sensitive prostate cancer and investing in precision medicine approaches including targeted alpha therapy for metastatic castration-resistant prostate cancer. Its subsidiary Vividion Therapeutics is developing small-molecule therapies enabled by chemoproteomics platforms, targeting previously "undruggable" disease drivers in cancer and immunology.

In women's health, Bayer is developing therapies targeting vasomotor symptoms associated with menopause, including those induced by endocrine treatment in breast cancer patients.

Bayer's pipeline gained momentum in 2025, supported by three product approvals, two new indications, and six positive Phase III trial outcomes. Looking ahead to 2026, the company expects key milestones across precision medicine, gene and cell therapies, and molecular imaging. Bayer is expanding into gene and cell therapy platforms through subsidiaries AskBio and BlueRock Therapeutics, targeting diseases including Parkinson's disease and inherited retinal disorders.

In medical imaging, Bayer is developing next-generation gadolinium-based MRI contrast agents with improved safety profiles and lower dosage requirements, as well as molecular imaging agents for detecting amyloid deposits.

Bayer's pharmaceutical business is beginning to see the light at the end of the tunnel created by Xarelto (rivaroxaban) generics and Eylea (aflibercept) biosimilars, as its new products Nubeqa (darolutamide) and Kerendia (finerenone) deliver double-digit sales growth. The company still has a ways to go to replace the revenue declines caused by losses of exclusivity in Europe for its two top-selling products, but the pipeline is helping to fill the gap.